Factors Associated With the Use of 360-Degree Laser Retinopexy During Primary Vitrectomy With or Without Scleral Buckle for Rhegmatogenous Retinal Detachment and Impact on Surgical Outcomes
Andrew Tye, MD  |  January 16, 2021
Continue Reading
Frequency of Rhegmatogenous Retinal Detachment after Intravitreal Therapy in Neovascular Age-Related Macular Degeneration
Priya Sharma Vakharia, MD  |  January 7, 2021
Continue Reading
Aqueous Chlorhexidine Compared to Povidone Iodine as Ocular Antisepsis Prior to Intravitreal Injection: A Randomized Clinical Trial
Daniel Su, MD  |  December 30, 2020
Continue Reading
Retinal Specialist versus Artificial Intelligence Detection of Retinal Fluid from OCT
Mohsin H. Ali, MD  |  December 19, 2020
Continue Reading
Intraocular Pressure Changes and Vascular Endothelial Growth Factor Inhibitor Use in Various Retinal Diseases: Long-Term Outcomes in Routine Clinical Practice: Data from the Fight Retinal Blindness! Registry
Rehan M. Hussain, MD  |  December 8, 2020
Continue Reading
Randomized Safety and Feasibility Trial of Ultra-Rapid Cooling Anesthesia for Intravitreal Injections
Akshay S. Thomas, MD  |  November 30, 2020
Continue Reading
Paracentral and Cecocentral Scotomas after Pars Plana Vitrectomy for Rhegmatogenous Retinal Detachment
Vlad Matei, MD  |  November 16, 2020
Continue Reading
Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice
Joshua D. Levinson, MD  |  November 10, 2020
Continue Reading
Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial
Judy Chen, MD  |  November 2, 2020
Continue Reading
C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial
Katherine E. Talcott, MD  |  October 21, 2020
Continue Reading
Vitrectomy as an Aerosol-Generating Procedure in the Time of COVID-19: The VAPOR Study
Prethy Rao, MD MPH  |  October 10, 2020
Continue Reading
Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration
Maxwell S. Stem, MD  |  September 30, 2020
Continue Reading